Letter from Respiri re: contracts

1 Last

Itrade123

282 Posts.

08/02/24

11:13

Post #: 72300602

Assume all shareholder received this? If you are not one, good to have public.

7th February 2024
1
Only Respiri Limited offers unique, patent protected, FDA-cleared medical devices for integration into RPM programs. Building on the hero wheezo®, with the recent addition of EchoSolv™ and now CONNEQT.
2
Having recognised the significant revenue opportunities Respiri Limited can provide, Cardiex (ASX:CDX) has entered into an exclusive RPM commercial distribution agreement with Respiri Limited by integrating Cardiex’s, FDA-cleared CONNEQT Pulse cardiovascular biomarker device into Respiri's comprehensive solution for Remote Patient Monitoring programs, further differentiating the Respiri Remote Patient Monitoring device portfolio.

Cardiovascular RPM that monitors more than simple blood pressure. Key Highlights:
Integrating CARDIEX's CONNEQT Pulsevascular biomarker device into Respiri's RPM programs, creates a comprehensive RPM cardiovascular solution that goes beyond simple blood pressure and includes other cardiovascular physiological parameters.

The combination of these data sets will provide Respiri’s Care Specialist team with unique clinical insights that can help drive better patient outcomes.

More comprehensive monitoring and data will drive further reductions in healthcare costs- critical to the risk-share and other contract types Respiri has and will secure in future with Accountable Care Organisations (ACO), Independent Physician Associations (IPAs) and insurers/payors.

CONNEQT Pulse device will provide opportunity for additional revenues for Respiri through improved cost savings in risk-share contracts and by securing additional RPM clients interested in the unique additional data that CONNEQT can provide the Respiri Care Specialists and decisions that this will likely facilitate.

	7th February 2024
1	Only Respiri Limited offers unique, patent protected, FDA-cleared medical devices for integration into RPM programs. Building on the hero wheezo®, with the recent addition of EchoSolv™ and now CONNEQT.
2	Having recognised the significant revenue opportunities Respiri Limited can provide, Cardiex (ASX:CDX) has entered into an exclusive RPM commercial distribution agreement with Respiri Limited by integrating Cardiex’s, FDA-cleared CONNEQT Pulse cardiovascular biomarker device into Respiri's comprehensive solution for Remote Patient Monitoring programs, further differentiating the Respiri Remote Patient Monitoring device portfolio. Cardiovascular RPM that monitors more than simple blood pressure. Key Highlights: Integrating CARDIEX's CONNEQT Pulsevascular biomarker device into Respiri's RPM programs, creates a comprehensive RPM cardiovascular solution that goes beyond simple blood pressure and includes other cardiovascular physiological parameters. The combination of these data sets will provide Respiri’s Care Specialist team with unique clinical insights that can help drive better patient outcomes. More comprehensive monitoring and data will drive further reductions in healthcare costs- critical to the risk-share and other contract types Respiri has and will secure in future with Accountable Care Organisations (ACO), Independent Physician Associations (IPAs) and insurers/payors. CONNEQT Pulse device will provide opportunity for additional revenues for Respiri through improved cost savings in risk-share contracts and by securing additional RPM clients interested in the unique additional data that CONNEQT can provide the Respiri Care Specialists and decisions that this will likely facilitate.